Literature DB >> 15104166

Assessing hydroxychloroquine toxicity by the multifocal ERG.

Michael N Moschos1, Marilita M Moschos, Michael Apostolopoulos, John A Mallias, Christos Bouros, George P Theodossiadis.   

Abstract

Twenty patients on Plaquenil treatment were evaluated for retinal toxicity using the (EOG) and the mfERG. Group 1 comprises 15 patients (30 eyes) with normal EOG. From these patients 11 (22 eyes) showed normal RRD of mfERG in area 1 and area 2. The rest four patients (8 eyes) the RRD were reduced. Six months after interruption of HC, the mfERG improved in three cases. Group 2 comprises 5 patients (10 eyes) with subnormal EOG. Four (8 eyes) of these showed a decrease of RRD of the mfERG in area 1 and 2. In the rest one (2 eyes) the RRD were normal. Six months after interruption of HC the mfERG and the EOG improved in 2 cases. These results postulate that the mfERG may be used as an alternative method, perhaps more sensitive, for the detection of the HC retinopathy and the follow up of the patients on hydroxychloroquine.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15104166     DOI: 10.1023/b:doop.0000018385.99215.0d

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   2.379


  11 in total

1.  Hydroxychloroquine retinopathy.

Authors:  R K Maturi; J C Folk; B Nichols; T T Oetting; R H Kardon
Journal:  Arch Ophthalmol       Date:  1999-09

2.  THE EOG IN CHLOROQUINE AND OTHER RETINOPATHIES.

Authors:  P GOURAS; R D GUNKEL
Journal:  Arch Ophthalmol       Date:  1963-11

3.  Unusual ocular lesions in a case of systemic lupus erythematosus.

Authors:  A CAMBIAGGI
Journal:  AMA Arch Ophthalmol       Date:  1957-03

4.  The field topography of ERG components in man--I. The photopic luminance response.

Authors:  E E Sutter; D Tran
Journal:  Vision Res       Date:  1992-03       Impact factor: 1.886

5.  Ocular damage in chloroquine therapy.

Authors:  U Nylander
Journal:  Acta Ophthalmol (Copenh)       Date:  1966

6.  Incidence of chloroquine retinopathy.

Authors:  H Voipio
Journal:  Acta Ophthalmol (Copenh)       Date:  1966

7.  Chloroquine retinopathy. Early detection by retinal threshold test.

Authors:  R E Carr; P Gouras; R D Gunkel
Journal:  Arch Ophthalmol       Date:  1966-02

8.  Multifocal ERG in chloroquine retinopathy: regional variance of retinal dysfunction.

Authors:  U Kellner; H Kraus; M H Foerster
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2000-01       Impact factor: 3.117

9.  Detection of color vision defects in chloroquine retinopathy.

Authors:  B L Vu; M Easterbrook; J K Hovis
Journal:  Ophthalmology       Date:  1999-09       Impact factor: 12.079

10.  Hydroxychloroquine. Seven-year experience.

Authors:  D R Tobin; G Krohel; R I Rynes
Journal:  Arch Ophthalmol       Date:  1982-01
View more
  11 in total

1.  Visual field and multifocal electroretinography and their correlations in patients on hydroxychloroquine therapy.

Authors:  Timothy Y Y Lai; Jasmine W S Ngai; Wai-Man Chan; Dennis S C Lam
Journal:  Doc Ophthalmol       Date:  2006-06-28       Impact factor: 2.379

2.  Comparison of different screening methods for chloroquine/hydroxychloroquine retinopathy: multifocal electroretinography, color vision, perimetry, ophthalmoscopy, and fluorescein angiography.

Authors:  Susann Missner; Ulrich Kellner
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-01-04       Impact factor: 3.117

3.  Early morpho-functional changes in patients treated with hydroxychloroquine: a prospective cohort study.

Authors:  Giulio Ruberto; Carlo Bruttini; Carmine Tinelli; Lorenzo Cavagna; Alessandro Bianchi; Giovanni Milano
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-08-27       Impact factor: 3.117

Review 4.  Ocular toxicity due to chloroquine and hydroxychloroquine: electrophysiological and visual function correlates.

Authors:  Radouil Tzekov
Journal:  Doc Ophthalmol       Date:  2005-01       Impact factor: 2.379

5.  Retinal disorders in northern Brazilian patients treated with chloroquine assessed by multifocal ERG.

Authors:  M Raster; F Horn; A Jünemann; A A M Rosa; G S Souza; B D Gomes; M G Lima; L C L Silveira; J Kremers
Journal:  Doc Ophthalmol       Date:  2011-02-03       Impact factor: 2.379

6.  Electrophysiologic findings in chloroquine maculopathy.

Authors:  Regina Halfeld Furtado de Mendonça; Otacílio Oliveira Maia; Walter Yukihiko Takahashi
Journal:  Doc Ophthalmol       Date:  2007-06-12       Impact factor: 2.379

7.  Assessment of hydroxychloroquine maculopathy after cessation of treatment: an optical coherence tomography and multifocal electroretinography study.

Authors:  Marilita M Moschos; Eirini Nitoda; Irini P Chatziralli; Zisis Gatzioufas; Chryssanthi Koutsandrea; George Kitsos
Journal:  Drug Des Devel Ther       Date:  2015-06-11       Impact factor: 4.162

8.  Hydroxychloroquine for treatment of rheumatoid arthritis: multifocal electroretinogram and laser flare-cell photometry study.

Authors:  Stefano Sebastiani; Michela Fresina; Mauro Cellini; Emilio C Campos
Journal:  Clin Ophthalmol       Date:  2017-04-11

9.  Spectral domain optical coherence tomography for early detection of retinal alterations in patients using hydroxychloroquine.

Authors:  Yigit Ulviye; Tugcu Betul; Tarakcioglu Hatice Nur; Celik Selda
Journal:  Indian J Ophthalmol       Date:  2013-04       Impact factor: 1.848

10.  Multifocal electroretinography after high dose chloroquine therapy for malaria.

Authors:  Aline Correa de Carvalho; Martin Schwarz; Givago da Silva Souza; Bruno Duarte Gomes; Alexandre Antônio Marques Rosa; Ana Maria Revoredo da Silva Ventura; José Maria de Souza; Luiz Carlos de Lima Silveira; Jan Kremers
Journal:  J Ophthalmic Vis Res       Date:  2013-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.